Change to the Notice of Orion Corporation’s Annual General Meeting

NEXT STORY
Study underway in Nova Scotia long-term care facilities to determine health factors related to severe COVID-19 outcomes and vaccine effectiveness
PREV STORY
Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with Vamorolone in Duchenne Muscular Dystrophy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting

author_avatar
NASDAQ Market News

OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

Phase 3 Trial received Approval to be Initiated in Israel Patient Accrual Already Resumed ...

author_avatar
NASDAQ Market News

Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing

author_avatar
NASDAQ Market News